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1582 Subject Index for Volume 62
RET, 715 (L)
Signaling pathway, 715 (L)
Retina, 1248 (L)
Degeneration, 192 (L)











Sanfilippo syndrome, 53, 64
Saudi Arabia, 295, 325
Scottish BRCA1/2, 1543 (L)
Season of birth, 1262 (L)
Segregation analysis, 738
Senescence, 1003 (R), 1008 (R), 1015 (R)
Sensorineural deafness, 27, 355, 1123
7-Biopterin, 1302





Short tandem repeat, 1408
Polymorphism, 1507






Level(s), 690, 996 (L)
Simple tandem-repeat polymorphism, 1389
Simulation(s), 994 (L), 996 (L)
Studies, 171
Single step, 1408
Single-strand conformational analysis, 286







Spinal muscular atrophy, 485, 486
Spinal neurofibromatosis, 834
Splice effectors, 269
Splice-site mutation(s), 70, 585
SSCP, 1034, 1361
Statistical genetics, 181




STRP (see Simple tandem-repeat polymorphism)
Sulfatases, 562
Survival motor neuron, 485, 486
T cells, 373, 1003 (R)
TAP, 215 (R)
Teeth, 987 (L)
Temperature sensitivity, 1539 (L)
Teratogenicity, 25 (E)
Testing, genetic, 736 (L)
Tetrahydrobiopterin, 1302
Threshold, 994 (L)
Tibial muscular dystrophy, 620
Tocopherol transfer protein, 301
Topoisomerase, 253
Transcript defect, 713 (L)
Transcription, 77
Defective/deficient, 111, 713 (L)





Transmission/disequilibrium test, 450, 703, 969
Triglyceride, 406








Two-stage strategy, 205 (L)











Subject Index for Volume 62 1583
Valvular dystrophy, 627
van Buchem disease, 391
Variance-component linkage analysis, 1198
Variegate porphyria, 1254 (L)
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